Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
COLUMN
How to Serve and Get Ahead
In 2019, Isaac Getz wrote the book L’Entreprise Altruiste, which is about companies that have made radical transformations for the greater good, with Japan’s Eisai being a prime example. In the early 1990s, Eisai’s new president, Haruo Naito, began to…
To read the full story
COLUMN
- Seven Recruitment Trends in 2023
May 31, 2023
- The Inflation Reduction Act - Implications for Japanese Pharmaceutical Manufacturers
May 19, 2023
- The Increasing Impact of Real-World Evidence
March 31, 2023
- Rewarding Value and Innovation and Ensuring Financial Viability of the Biopharmaceutical Supply Chain in Japan
March 16, 2023
- Why Market Mapping Is Critical to Your Organization
February 24, 2023
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…